Authors
Latest:
Dr. Volpe Discusses the Management of Localized Kidney CancerAlessandro Volpe, MD, University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy, discusses the management of locally advanced kidney cancer.
Latest:
Dr. Adjei on Adverse Events From MEK InhibitorsAlex A. Adjei, MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia Chair in Cancer Medicine, Senior Vice President, Clinical Research, Roswell Park Cancer Institute, discusses eye toxicity from MEK inhibitors.
Latest:
Dr. Denes Discusses Biosimilar Pricing in OncologyAlex E. Denes, MD, associate professor of medicine, School of Medicine, Oregon Health and Science University, discusses biosimilar pricing in oncology.
Latest:
Dr. Herrera on the Potential for Frontline CAR T-Cell Therapy in DLBCLAlex Herrera, MD, discusses the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma.
Latest:
Alex Molasiotis, RN, PhD, on the Management on BreathlessnessAlex Molasiotis, RN, PhD, discusses the results of a pilot feasibility study looking at inspiratory muscle training for the management of breathlessness in patients with lung cancer.
Latest:
Dr. Olawaiye on How to Address Disparities in Cancer CareAlexander B. Olawaiye, MD, discusses how to address disparities in cancer care.
Latest:
Dr. Drilon on the FDA Approval of Selpercatinib in RET Fusion+ Solid TumorsAlexander Drilon, MD, discusses the significance of the FDA approval of selpercatinib in RET fusion–positive solid tumors.
Latest:
Rapid Readouts: Results from two trials of TRK inhibitor, larotrectinib, in patients with TRK fusion-positive lung cancerAlexander Drilon, MD presents data from the 2021 American Society of Clinical Oncology annual meeting from trials in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive lung cancer treated with larotrectinib.
Latest:
Dr. Drilon on Activity of Larotrectinib in TRK Fusion-Positive NSCLCAlexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the activity of larotrectinib (Vitrakvi) in patients with TRK fusion–positive non–small cell lung cancer.
Latest:
Dr. Perl on CAR T Cells in Pediatric LeukemiaAlexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, Perelman School of Medicine, discusses the promise of CAR T cells in the treatment of pediatric leukemia.
Latest:
Dr. Perl on Genetic Testing and Targeted Therapies in AMLAlexander E. Perl, MD, MS, associate professor, medicine, the Hospital of the University of Pennsylvania, discusses why genetic testing is important for determining targeted therapies for patients with acute myeloid leukemia.
Latest:
Dr. Guminski on 16-Month Follow-Up With Cemiplimab in mCSCCAlexander Guminski, MD, PhD, medical oncologist, Royal North Shore Hospital, University of Sydney, discusses the 16-month follow-up results of a phase II trial evaluating cemiplimab (Libtayo) in patients with metastatic cutaneous squamous cell carcinoma.
Latest:
Dr. Stratigos the Rationale to Evaluate Cemiplimab in Locally Advanced BCCAlexander J. Stratigos, MD, discusses the rationale to evaluate cemiplimab-rwlc in locally advanced basal cell carcinoma.
Latest:
Fox Chase Investigates Screening Methods to Avoid Unnecessary Radical CystectomyCurrently, there is no reliable way to identify who can safely avoid radical cystectomy following MIBC treatment. For this reason, Fox Chase Cancer Center researchers are trying to find the as-yet-elusive 30% by asking 3 important questions.
Latest:
Dr. Kutikov on Tumor Pathology in Renal Cell CarcinomaAlexander Kutikov, MD, FACS, attending surgeon, urologic oncology, associate professor, urologic oncology, Fox Chase Cancer Center, discusses the understanding of tumor pathology in renal cell carcinoma.
Latest:
Dr. Lazarides on Research Regarding Margin Assessment in SarcomaAlexander Leandros Lazarides, MD, discusses research regarding margin assessment in patients with sarcoma.
Latest:
Dr. Lesokhin on the Utility of Elranatamab in Relapsed/Refractory Multiple MyelomaAlexander M. Lesokhin, MD, discusses the utility of elranatamab in the ongoing phase 2 MagnetisimMM-3 trial in relapsed/refractory multiple myeloma.
Latest:
Dr. Eggermont on the Rationale for Evaluating Adjuvant Pembrolizumab in Advanced MelanomaAlexander M. M. Eggermont, MD, PhD, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, evaluating adjuvant pembrolizumab versus placebo, in advanced melanoma.
Latest:
Dr. Shoushtari on the Rationale for the CheckMate-067 Trial in Advanced MelanomaAlexander N. Shoushtari, discusses the rationale for the phase 3 CheckMate-067 trial in advanced melanoma.
Latest:
Dr. Menter on Neoadjuvant Immunotherapy in Early-Stage NSCLCAlexander R. Menter, MD, oncologist, Kaiser Permanente, discusses the use of neoadjuvant immunotherapy in patients with early-stage non–small cell lung cancer (NSCLC).
Latest:
Dr. Ring on Molecular Profiling of CTCs in Advanced Breast CancerAlexander Ring, MD, graduate student, University of Southern California, discusses a study investigating the molecular profiling of circulating tumor cells (CTCs) as a surrogate for distant metastasis in patients with stage IV breast cancer.
Latest:
Dr. Spira on the FDA Approval of Adagrasib in KRAS G12C–mutant NSCLCAlexander I. Spira, MD, PhD, FACP, discusses the FDA approval of adagrasib in patients with KRAS G12C–mutated non–small cell lung cancer.
Latest:
Dr. Spira on the CNS Activity of Adagrasib in NSCLCAlexander I. Spira, MD, PhD, FACP, discusses the activity of adagrasib in patients with non–small cell lung cancer and central nervous system metastases.
Latest:
Dr. Drakaki on the Design of the MORPHEUS-mUC Trial in Urothelial CarcinomaAlexandra Drakaki, MD, discusses the design of the MORPHEUS-mUC trial in advanced/metastatic urothelial carcinoma.
